

CS/BSE/NSE/PR/2019-2020

April 22, 2019

**To**  
**The General Manager**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400 001**

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**

**Stock Code: 530239**

**Stock Code: SUVEN - EQ**

Dear Sir/Madam,


**Sub: Press Release**

.....

With reference to above subject, please find enclosed Press Release of our company titled **“Suven completes the purchase of assets of Rising Pharmaceuticals through its joint venture partner, Shore Suven Pharma Inc.”**

This is for your information and record.

Thanking You,  
Yours faithfully,  
For **Suven Life Sciences Limited**

  
**K. Hanumantha Rao**  
Company Secretary

## Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)

## News Release

### **Suven completes the purchase of assets of Rising Pharmaceuticals through its joint venture partner, Shore Suven Pharma Inc.**

**HYDERABAD, INDIA (April 22, 2019) – Suven Life Sciences Limited**, a biopharmaceutical company provider of Contract Research and Manufacturing Services (CRAMS) for global life science companies, announced today that it has completed the previously disclosed purchase of the assets of Rising Pharmaceuticals and Rising’s subsidiaries to Shore Suven Pharma, Inc.

“This brings closure of the purchase process for the assets of Rising Pharmaceuticals and paves the way for a seamless transition of the portfolio, customer programs and manufacturing and drug development relationships to Shore Suven Pharma Inc. which in turn will pave the way for continuity of product supply to the customers,” said Mr. Venkat Jasti, CEO of Suven Life Sciences Ltd.

*Risk Statement:*

*Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*

## **Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)